SELECT PUBLICATIONS

BCIRG. Interim analysis of phase III study shows Taxotere^® (docetaxel)-based chemotherapy regimens combined with Herceptin^® (trastuzumab) significantly improved disease free survival in early-stage HER2-positive breast cancer [press release]. September 15, 2005. Abstract

Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med 2005;353:1652-54. No abstract available

Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-6. No abstract available

Perez EA. Further analysis of NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Presentation. ASCO 2005. Abstract 556

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. Abstract

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. Abstract

Slamon DJ. Antibody-based therapeutics: More than a one-trick pony. Presentation. ASCO 2005. No abstract available